منابع مشابه
G-CSF and GM-CSF in Neutropenia.
G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias. ...
متن کاملG-CSF and GM-CSF in clinical trials.
Hematopoietic growth factors have now been purified, cloned, and produced in bacteria and yeast. Those that are currently in clinical study include erythropoietin, GM-CSF, G-CSF, M-CSF (also called CSF-1), and multi-CSF (also called interleukin 3). Growth factor appear likely to enhance the recovery and function of circulating white cells after standard-dose cancer therapy and high-bone-dose ca...
متن کاملG-CSF and GM-CSF on tumor peogression
JBUON 2017; 22(1): 21 GM-CSF and G-CSF are capable to regulate the maturation of undifferentiated multipotent stem cells into mature granulocytes, macrophages and T cells in the bone marrow. Thereby, clinicians correct neutropenia induced by chemotherapy or radiation routinely with recombinant Gor GM-CSFs in clinical practice. However, relevant studies found that treatment for cancer patients w...
متن کاملGrowth Factors G-CSF and GM-CSF: Clinical Options
The body's immediate response to bacterial infection becomes clinically evident as an inflammatory reaction accompanied by an acute-phase response in the liver and hyperthermia. Activation of the immune system must be counterregulated to curb these processes and to prevent (or at least minimize) damage to the host tissue. The major part of this intricate regulation is performed by the cytokine ...
متن کاملNeutropenia and G-CSF in lymphoproliferative diseases
BACKGROUND Chemotherapy-induced neutropenia is a major cause of morbidity and mortality. It frequently causes dose reductions or treatment delay, which can be prevented or treated by the administration of granulocyte-colony-stimulating factor (G-CSF). However, a better knowledge of the incidence, day of onset after therapy, and duration of neutropenia is essential to optimize the use of G-CSF. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Immunology
سال: 2015
ISSN: 0022-1767,1550-6606
DOI: 10.4049/jimmunol.1500861